Brought to you by 
Quintiles Transnational nets $496mm through IPO
19 Aug 2013
Executive Summary
CRO Quintiles Transnational Holdings Inc. has netted $496mm through its initial public offering of 13mm common shares at $40. Existing shareholders also sold 10.6mm shares and covered an overallotment of 3.6mm shares. When the company filed back in February, it had hoped to bring in about $600mm, of which half was to be used to repay a term loan.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com